Related Experiment Video

Updated: Jun 18, 2026

Cell-Based Drug Screening for Inhibitors of Autophagy Related 4B Cysteine Peptidase
09:51

Cell-Based Drug Screening for Inhibitors of Autophagy Related 4B Cysteine Peptidase

Published on: June 30, 2023

Cathepsin L, target in cancer treatment?

Jacqueline M Lankelma1, Daniëlle M Voorend, Temo Barwari

  • 1Department of Cell Biology and Histology, Academic Medical Center, University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands. Jacqueline.Lankelma@student.uva.nl

Life Sciences
|December 5, 2009
PubMed

Insights

Cathepsin L inhibition shows potential in slowing cancer progression by reducing invasion and metastasis. Combining cathepsin L inhibition with chemotherapy appears more effective than monotherapy for cancer treatment.

Area of Science:

  • Oncology
  • Biochemistry
  • Molecular Biology

Background:

  • Cathepsin L, a cysteine protease, plays a role in cancer development and progression.
  • Targeting proteases is a strategy to inhibit cancer growth.

Purpose of the Study:

  • To review recent studies on cathepsin L inhibition in cancer treatment.
  • To evaluate the efficacy of cathepsin L inhibition as a monotherapy versus combination therapy.

Main Methods:

  • Literature review of studies investigating cathepsin L inhibitors in cancer.
  • Analysis of effects on apoptosis, angiogenesis, invasion, and metastasis.
  • Assessment of compensatory mechanisms by other proteases.

Main Results:

  • Monotherapy with cathepsin L inhibition has ambiguous effects on apoptosis and angiogenesis.
  • Cathepsin L inhibition appears to reduce cancer invasion and metastasis.
  • Concerns exist regarding compensatory activity of other cathepsins with selective inhibition.

Conclusions:

  • Combination therapy of cathepsin L inhibition with conventional chemotherapy shows more consistent and promising results.
  • Future research should focus on the mechanisms and effects of combination therapy for cancer treatment.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...